Closeup4

ACCESSIBILITY

Model is not an actual patient.

The Site is brought to you by Sinclair Pharma Ltd (Sinclair). Our registered office is 30-32 Whitfield Street, Whitfield Court, London, W1T 2RQ with company registration number 03816616.

Sinclair recognises the importance of providing a website that is accessible to all user groups including people with disabilities such as blindness and low vision, deafness and hearing loss, learning disabilities, cognitive limitations, limited movement, speech disabilities, photosensitivity and combinations of these.

Sinclair has designed the Site with accessibility in mind, following the guidelines laid down by the W3C Web Accessibility Initiative (WAI).

Web Content Accessibility Guidelines (WCAG) 2.0 covers a wide range of recommendations for making web content more accessible to a wider range of people with disabilities and will also often make web content more usable to users in general.

The 12 accessibility guidelines are:

  • Provide text alternatives for non-text content.
  • Provide captions and alternatives for audio and video content.
  • Make content adaptable; and make it available to assistive technologies.
  • Use sufficient contrast to make things easy to see and hear.
  • Make all functionality keyboard accessible.
  • Give users enough time to read and use content.
  • Do not use content that causes seizures.
  • Help users navigate and find content.
  • Make text readable and understandable.
  • Make content appear and operate in predictable ways.
  • Help users avoid and correct mistakes.
  • Maximize compatibility with current and future technologies.
  • There are three levels of conformance to the accessibility guidelines: A (lowest), AA, and AAA (highest) and our aim is to conform to AA Level. However these are guidelines only and in some instances it is not practical to conform exactly to all checkpoints. If you have any queries about the accessibility of this website please contact enquiries@sinclairpharma.com

Content regarding Lanluma® is not intended for patients and healthcare professionals based in Germany.

Die Inhalte zu Lanluma® sind nicht für Patienten und Ärzte mit Sitz in Deutschland bestimmt.

INDICATION

Lanluma is a poly-L-lactic acid implant suitable for increasing the volume of depressed areas, particularly to correct skin depressions

IMPORTANT SAFETY CONSIDERATIONS

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them.

Content regarding Lanluma® is not intended for patients and healthcare professionals based in Germany.

Die Inhalte zu Lanluma® sind nicht für Patienten und Ärzte mit Sitz in Deutschland bestimmt.

INDICATION

Lanluma is a poly-L-lactic acid implant suitable for increasing the volume of depressed areas, particularly to correct skin depressions.

IMPORTANT SAFETY CONSIDERATIONS

Like all procedures of this type there is a possibility of adverse events, although not everybody experiences them. These adverse events include but are not limited to infection, minimal acute inflammatory tissue reaction (redness, swelling, rash, oedema, erythema, lumps/nodules etc.), pain (which may be temporary or persistent in nature), transient haematoma or bruising. For a full list consult Instructions for Use.

The onset of any side effect must be reported immediately. Please contact the local Sinclair representative or authorised Lanluma distributor. Alternatively send the details to Sinclair on: quality@sinclairpharma.com

For a full list of contraindications, warnings and precautions for this product please visit https://www.sinclairpharma.com/eifu for copy of the Product Instructions for Use.